This company develops immunotherapies by utilizing immune organoids and artificial intelligence to design drugs that function effectively in humans from the initial stages. Their platform aims to accelerate drug discovery timelines and reduce development costs by testing candidates in realistic, patient-matched disease models. By integrating human data early, they seek to deliver safer, more effective therapies with fewer side effects across diverse populations.
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug development relies heavily on animal models, which often fail to accurately predict human responses, leading to high failure rates, increased costs, and prolonged timelines. This reliance on animal testing also raises ethical concerns and limits the ability to efficiently screen and develop effective immunotherapies.
Solution
Parallel Bio offers a human-centric drug discovery platform that utilizes immune organoids and artificial intelligence to design and test immunotherapies in human-like environments. By replacing animal models with scaled, functioning replicas of human lymph nodes, the platform generates novel immune data at unprecedented rates. This data is then used to drive AI-powered drug discovery, enabling the identification and verification of drug candidates in vitro across a diverse population. This approach aims to reduce the risk, time, and cost associated with traditional drug development, while increasing the likelihood of bringing safe and effective therapies to patients.
Target Audience
The primary customers are pharmaceutical and biotechnology companies seeking to accelerate and improve the efficiency of their immunotherapy drug development programs.
Features
- High-throughput automation for scaling immune organoid populations
- Generation of novel immune training data from diverse organoid populations
- AI-powered drug discovery engine for identifying promising drug candidates
- In vitro verification of drug candidates across a massive population
- Disease modeling capabilities using patient-matched organoid models
- Target discovery using healthy and disease organoids to identify novel drug targets
- Prediction of drug safety in a diverse representation of the population